Literature DB >> 4401309

Analysis of the inhibition of pethidine N-demethylation by monoamine oxidase inhibitors and some other drugs with special reference to drug interactions in man.

B Clark, J W Thompson, G Widdrington.   

Abstract

1. N-Demethylation of pethidine was studied in microsomal suspensions from unstarved male rat liver and the N-demethylase identified as belonging to the class of hepatic microsomal mixed function oxidases.2. A study of the structure/action relationships of compounds inhibiting pethidine N-demethylase revealed that hydrazine derivatives including phenylhydrazine, methylphenylhydrazine and mebanazine were all potent competitive inhibitors.3. Pethidine N-demethylase was only slightly inhibited by histamine and amphetamine but not by adrenaline and ephedrine nor by several miscellaneous compounds including piperidine, N-ethylpiperidine, N-methylpiperidine, N-methylammonium, hydrallazine or pethidinic acid.4. Several psychotropic drugs were all found to be potent competitive inhibitors of pethidine N-demethylase. These included monoaminoxidase inhibitors (the most active being nialamide and phenoxypropazine [K(i)=0.01 mM]; the least active iproniazid [K(i)=1.05 mM]); the tranquillizers promazine, propiomazine and chlorpromazine and tricyclic antidepressants (opipramol [K(i)=0.01 mM], imipramine [K(i)=0.03 mM], desipramine [K(i)=0.03 mM] and amitryptyline [K(i)=0.03 mM]). Hydrocortisone [K(i)=0.3 mM], prednisolone [2.8 mM] and nalorphine [0.07 mM] were also inhibitors, whilst SKF 525A was the most active of all [K(i)=0.002 mM].5. These results are discussed in relation to the clinically observed drug interactions which may occur between monoamineoxidase inhibitors and pethidine. It is concluded that since many different groups of drugs, including monoamineoxidase inhibitors, tranquillizers, tricyclic antidepressants, steroids, nalorphine, SKF 525A and barbiturates compete for cytochrome P(450) reductase, it is possible that this mechanism may account, at least in part, for the observed interactions of these various drugs in man.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4401309      PMCID: PMC1665689          DOI: 10.1111/j.1476-5381.1972.tb07241.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

1.  DANGEROUS POTENTIATION OF MEPERIDINE HYDROCHLORIDE BY PARGYLINE HYDROCHLORIDE.

Authors:  I M VIGRAN
Journal:  JAMA       Date:  1964-03-21       Impact factor: 56.272

2.  P-AMINOSALICYLIC ACID INDUCED PROLONGATION OF HEXOBARBITAL SLEEPING TIME.

Authors:  L A ROGERS; G A ALCANTARA; J R FOUTS
Journal:  J Pharmacol Exp Ther       Date:  1963-11       Impact factor: 4.030

3.  Studies on an N-demethylating system in rat liver microsomes.

Authors:  J S ROTH; J BUKOVSKY
Journal:  J Pharmacol Exp Ther       Date:  1961-03       Impact factor: 4.030

4.  The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2.

Authors:  C J LAMBERTSEN; H WENDEL; J B LONGENHAGEN
Journal:  J Pharmacol Exp Ther       Date:  1961-03       Impact factor: 4.030

5.  Toxic effects of iproniazid in a patient with angina.

Authors:  C PAPP; S BENAIM
Journal:  Br Med J       Date:  1958-11-01

6.  The enzymatic N-demethylation of narcotic drugs.

Authors:  J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1956-07       Impact factor: 4.030

7.  Function of cytochrome P-450 of microsomes.

Authors:  T Omura; R Sato; D Y Cooper; O Rosenthal; R W Estabrook
Journal:  Fed Proc       Date:  1965 Sep-Oct

8.  Desipramine and amphetamine metabolism.

Authors:  S Consolo; E Dolfini; S Garattini; L Valzelli
Journal:  J Pharm Pharmacol       Date:  1967-04       Impact factor: 3.765

9.  Inhibition of drug metabolism. I. Kinetics of the inhibition of the N-demethylation of ethylmorphine by 2-diethylaminoethyl 2,2-diphenylvalerate HC1 (SKF 525-A) and related compounds.

Authors:  M W Anders; G J Mannering
Journal:  Mol Pharmacol       Date:  1966-07       Impact factor: 4.436

10.  The physiological disposition and fate of meperidine (demerol) in man and a method for its estimation in plasma.

Authors:  J J BURNS; B L BERGER; P A LIEF; A WOLLACK; E M PAPPER; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1955-07       Impact factor: 4.030

View more
  9 in total

Review 1.  Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review.

Authors:  G B Baker; R T Coutts; K F McKenna; R L Sherry-McKenna
Journal:  J Psychiatry Neurosci       Date:  1992-11       Impact factor: 6.186

2.  Effects of tetrabenazine and phenylpiperidine analgesics during daily clorgyline treatment.

Authors:  J D Leander
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

Review 3.  Clinical pharmacokinetics of pethidine: 1982.

Authors:  D J Edwards; C K Svensson; J P Visco; D Lalka
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

4.  Interactions of iprindole with fenfluramine metabolism in rat brain and liver.

Authors:  K M Hegadoren; G B Baker; R T Coutts; W G Dewhurst
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

5.  Interactions between sympathomimetic amines and antidepressant agents in man.

Authors:  A J Boakes; D R Laurence; P C Teoh; F S Barar; L T Benedikter; B N Prichard
Journal:  Br Med J       Date:  1973-02-10

Review 6.  Pharmacokinetic drug interactions in anaesthetic practice.

Authors:  M Wood
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

7.  Antipyrine elimination by patients under treatment with monoamine oxidase inhibitors.

Authors:  S E Smith; J Lambourn; P J Tyrer
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

8.  Metabolism of phenazone in man after hydrocortisone administration.

Authors:  J Elfström; S Lindgren
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

9.  Inhibitory effects of the monoamine oxidase inhibitor tranylcypromine on the cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6.

Authors:  Mahnaz Salsali; Andrew Holt; Glen B Baker
Journal:  Cell Mol Neurobiol       Date:  2004-02       Impact factor: 5.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.